Publication details
Metformin therapy and risk of cancer in patients after heart transplantation
| Authors | |
|---|---|
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Bratislava Medical Journal - Bratislavské lekárske listy |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1 |
| Doi | http://dx.doi.org/10.4149/BLL_2021_051 |
| Keywords | biguanide; heart graft; malignancy; diabetes mellitus; survival |
| Description | BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to find out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient's survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a significantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19). Text in PDF www.elis.sk |